A new positron emission tomography (PET) developed by Merck can enter the brains of people with Parkinson’s and highlight the toxic alpha-synuclein fibrils responsible for nerve cell loss, a small first-in-human study shows. Working with the Michael J. Fox Foundation for Parkinson’s Research (MJFF), researchers recruited eight…
News
April is Parkinson’s Awareness Month and, in the U.S. and across the globe this year, patients, caregivers, medical professionals, and advocates will be focusing their attention on helping to empower those living with the neurological disease by providing educational resources, fostering community, and providing opportunities to get involved. World Parkinson’s…
A new positron emission tomography (PET) radiotracer can accurately visualize inflammation within the healthy human brain, a first-in-human study found. By using a marker that binds to COX-2, a key enzyme associated with brain inflammation or neuroinflammation, researchers were able to quantify low levels of this enzyme in healthy individuals.
A new collaborative effort between Mayo Clinical Laboratories and Amprion will expand access to the diagnostic company’s SAAmplify–αSYN test — designed to detect the presence of abnormal alpha-synuclein protein in people suspected of having neurodegenerative diseases — across the U.S., according to a joint press release.
Lecigon, an intestinal gel formulation of levodopa, entacapone, and carbidopa, provided sustained motor symptom control for people with advanced Parkinson’s disease, according to interim, one-year analyses from a real-world study in Europe. The treatment, which is approved in several European countries and Australia, but not the U.S.,…
Researchers at the University of Delaware have developed a model that combines artificial intelligence with magnetic resonance elastography (MRE) to measure brain stiffness and volume for predicting brain age. MRE is a noninvasive method that can measure changes in brain stiffness by using a gentle vibration of a person’s head…
Irlab Therapeutics is moving its oral candidate, IRL757, into a Phase 1b clinical study to assess its safety and explore early signs of efficacy in treating apathy in people with Parkinson’s disease. Patient enrollment is expected to begin in the second half of 2025. Financial support for the trial…
A rare mutation in the LRRK2 gene found in 17 individuals with Parkinson’s disease or a family history of Parkinson’s — all of European ancestry with a shared genetic background — appears to be a likely cause of the condition, according to a study of thousands of people. The…
Older adults with tremor are three times more likely than those in the general elderly population to develop Parkinson’s disease — especially if they act out their dreams while sleeping or experience new-onset rest tremor — a study from China has found. That study aimed “to explore predictive factors”…
Physical exercise eased signs of a type of iron-mediated cell death called ferroptosis in microglia and improved neurological function in mouse models of Parkinson’s disease, a study finds. Microglia are a type of nervous system support cell that’s believed to be important in the neurodegenerative disease. When ferroptosis was…
Recent Posts
- Pushing forward this Parkinson’s Awareness Month with boldness, grace
- Personalized DBS for Parkinson’s may result from brain study in China
- Fecal transplants ease motor symptoms in early Parkinson’s: Study
- ‘Moving Day, A Walk for Parkinson’s’ marks 15th year with events across US
- Choosing when to share a Parkinson’s diagnosis isn’t one-size-fits-all